5 completed, 3 not yet recruiting, 3 unknown, 2 active not recruiting. 5 Not applicable, 5 Phase 3, 4 Phase 2, 3 Phase 1, 2 Phase 4.
Follow amino-acid, glucose, and electrolyte solution: new trials by email Literature Review of amino-acid, glucose, and electrolyte solution trials Research Report on amino-acid, glucose, and electrolyte solution
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Amino Acid Therapy Evaluating the Incidence of New-Onset AKI Amino Acid infusion, Lactated Ringer Solution - Acute Kidney Injury | Phase 2 | Not yet recruiting | Children's Hospital Medical Center, Cincinnati | 270 | 2027-10-01 | 2026-10-21 |
| Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors Lutetium Lu 177-Edotreotide, Amino Acid Solution - Somatostatin Receptor Positive, NETs | Phase 1 | Recruiting | ITM Solucin GmbH | 20 | 2025-09-26 | 2026-10-27 |
| Amino Acids for Cardiac Surgery Associated AKI Amino Acids, Placebo - Acute Kidney Injury | Phase 2 | Not yet recruiting | Stanford University | 30 | 2025-09-01 | 2025-06-03 |
| Randomized Interval Assessment Trial of Lu177-Dotatate in Slowly Progressive G1-2 Advanced Midgut Neuroendocrine Tumors 177Lu-Dotatate (7.4 Gigabecquerel/cycle) during 30 min intravenous infusion every 16 weeks (q8w) x 4 cycles; 2) and 3) as in the experimental arm., 177Lu-Dotatate (7.4 Gigabecquerel/cycle) during 30 min intravenous infusion every 8 weeks (q8w) x 4 cycles; 2) and 3) as in the experimental arm., Amino acid solution - Grade1-2 Advanced Midgut Neuroendocrine Tumors (NETs) | Phase 3 | Recruiting | Grupo Espanol de Tumores Neuroendocrinos | 166 | 2025-06-12 | 2026-09-16 |
| Perioperative Use of Amino Acids in Recipients of Orthotopic Liver Transplantation as a Renal Protective Factor Amino acid solution, Amino Acid infusion - Hepatic Failure, Liver Transplant | Not applicable | Not yet recruiting | Hospital Dr Sotero del Rio | 90 | 2025-05-27 | 2025-06-04 |
| 177Lu-DOTA-EB-TATE in Adult Patients With Advanced, Well- Differentiated Neuroendocrine Tumors 177Lu-DOTA-EB-TATE, Amino Acid Solution - Neuroendocrine Tumors | Phase 1 | Completed | Molecular Targeting Technologies, Inc. | 6 | 2022-06-18 | 2026-10-26 |
| Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE 177Lu-Edotreotide (Peptide Receptor Radionuclide Therapy) PRRT, CAPTEM (Capecitabine and Temozolomide), Amino-Acid Solution - Neuroendocrine Tumors | Phase 3 | Active not recruiting | ITM Solucin GmbH | 259 | 2021-12-21 | 2025-09-10 |
| Study to Evaluate the Safety and Preliminary Efficacy of 177Lu-OPS201 in NETs Satoreotide tetraxetan, Amino acid solution, Antiemetic - Neuroendocrine Tumors | Phase 1 / Phase 2 | Terminated | Ipsen | 40 | 2017-03-06 | 2023-07-19 |
| Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients 177Lu-edotreotide PRRT, Everolimus, Amino-Acid Solution - Neuroendocrine Tumors | Phase 3 | Active not recruiting | ITM Solucin GmbH | 324 | 2017-02-02 | 2026-10-20 |
| Amino Acids in Ileal Pouch-anal Anastomosis for Ulcerative Colitis Vaminolac, Saline - Ulcerative Colitis | Not applicable | Unknown | Aarhus University Hospital | 8 | 2015-09-01 | 2017-07-28 |
| Enhancing the Anabolic Effect of Perioperative Nutrition With Insulin While Maintaining Normoglycemia Travasol (amino acid injection), Insulin - Colorectal Cancer | Phase 4 | Withdrawn | McGill University Health Centre/Research Institute of the McGill University Health Centre | 2013-12-01 | 2026-10-08 | |
| Amino Acid Infusion in Mothers Before and During Cesarean Delivery Amino acid solution, Ringer's lactate solution - Hypothermia | Not applicable | Completed | B.P. Koirala Institute of Health Sciences | 76 | 2013-06-01 | 2019-03-15 |
| Local Effects of Amino Acids and 3-hydroxybutyrate in the Bilaterally Perfused Human Leg Vamin (Fresenius Kabi), 3hydroxybutyrate - Critical Illness, Protein Metabolism | Not applicable | Unknown | University of Aarhus | 10 | 2011-09-01 | 2016-03-03 |
| Modulation of Systemic Inflammatory Response in Critically Ill Children After Glutamine Supplementation solution of amino acids supplemented with glutamine, amino acids not supplemented with glutamine - Inflammatory Response, Multi-organ Failure | Phase 4 | Completed | Hospital Sant Joan de Deu | 101 | 2010-04-01 | 2013-09-06 |
| Determination of Lysine Requirement in the Parenterally Fed Neonate Amino Acid Solution with different amount of Lysine - Parenteral Lysine Requirements, Parenteral Feedings | Not applicable | Completed | The Hospital for Sick Children | 6 | 2008-07-01 | 2013-08-05 |
| Cysteine Supplementation in Critically Ill Neonates Parenteral cysteine-HCl supplementation, Placebo - added premasol - Sepsis, Bronchopulmonary Dysplasia | Phase 2 / Phase 3 | Unknown | University of California, Los Angeles | 108 | 2006-09-01 | 2010-02-26 |
| Glutamine Supplementation to Prevent Death or Infection in Extremely Premature Infants Glutamine, Placebo - Infant, Newborn, Infant, Low Birth Weight | Phase 3 | Completed | NICHD Neonatal Research Network | 1433 | 1999-07-01 | 2015-06-08 |
Neuroendocrine Tumors (6) · Acute Kidney Injury (3) · Gastro-enteropancreatic neuroendocrine tumor (2) · Hyperphagia (2) · Sepsis (2) · Bronchopulmonary Dysplasia (1) · Central Nervous System Neoplasms (1) · Colitis, Ulcerative (1) · Colorectal Neoplasms (1) · Critical Illness (1) · Enterocolitis, Necrotizing (1) · Hyperinsulinism (1) · Hypothermia (1) · Liver Failure (1) · Lymphoma (1)
ITM Solucin GmbH (3) · Aarhus University Hospital (1) · B.P. Koirala Institute of Health Sciences (1) · Children's Hospital Medical Center, Cincinnati (1) · Grupo Espanol de Tumores Neuroendocrinos (1) · Hospital Dr Sotero del Rio (1) · Hospital Sant Joan de Deu (1) · Ipsen (1) · McGill University Health Centre/Research Institute of the McGill University Health Centre (1) · Molecular Targeting Technologies, Inc. (1) · NICHD Neonatal Research Network (1) · Stanford University (1) · The Hospital for Sick Children (1) · University of Aarhus (1) · University of California, Los Angeles (1)
United States (8) · France (5) · Spain (5) · Australia (3) · Canada (3) · Denmark (3) · United Kingdom (3) · Austria (2) · Germany (2) · Italy (2) · Netherlands (2) · Switzerland (2) · Belgium (1) · Chile (1) · China (1)
Abbot R. Laptook, MD (1) · Avroy A. Fanaroff, MD (1) · Barbara J. Stoll, MD (1) · Brenda B. Poindexter, MD MS (1) · Charles R. Bauer, MD (1) · David K. Stevenson, MD (1) · Edward F. Donovan, MD (1) · Eric Baudin Baudin, M.D., Ph.D. (1) · Iolanda Jordan, PhMD (1) · Jon E. Tyson, MD MPH (1) · Karen Chapman, RN, PhD (c) (1) · Krishna Pokharel, MD (1) · Lisa Bodei, MD, PhD (1) · Lu-Ann Papile, MD (1)
PMID 33006765, PMID 10950834, PMID 12600870, PMID 15121931, PMID 16356432, PMID 16615955, PMID 16818526, PMID 17908750, PMID 18716628, PMID 19403482, PMID 20164307, PMID 21336114, PMID 23325919, PMID 30783674, PMID 33789610, PMID 36292086, PMID 37526194, PMID 37721581, PMID 38528164, PMID 42392118
2015 (1), K08HD052885 (1), M01RR000070 (1), M01RR000750 (1), M01RR000997 (1), M01RR001032 (1), M01RR006022 (1), M01RR008084 (1), U01HD036790 (1), U10HD021364 (1), U10HD021373 (1), U10HD021385 (1), U10HD021397 (1), U10HD021415 (1), U10HD027851 (1)